Slingshot members are tracking this event:

Bristol-Myers Squibb (BMY) Releases Phase 3 ONO-4538-12 Results Evaluating Opdivo in Patients with Unresectable Advanced or Recurrent Gastric Cancer Resistant to Standard Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Ono-4538-12, Opdivo, Unresectable Advanced, Recurrent, Gastric Cancer, Resistant To Standard Therapy